Kensington Hospital is a licensed substance use treatment provider in Philadelphia, PA, listed in the SAMHSA treatment directory. It offers hospital inpatient care with medical staff on site around the clock. Clients can live on site in a residential program while they complete treatment. Outpatient care is offered, so clients can keep living at home between scheduled sessions. On site detox services are available, so withdrawal can be managed before treatment begins. Methadone is available as part of medication assisted treatment for opioid use disorder. Buprenorphine (Suboxone) is offered to reduce opioid cravings and lower relapse and overdose risk. Naltrexone is used to support recovery from opioid or alcohol use disorder. The program treats co-occurring mental health conditions alongside addiction. The facility reports accepting Medicaid. It serves young adults, adults, seniors.
Availability and current services change often. Call (888) 470-5244
and we will help you confirm openings, insurance, and next steps.
Methadone used in TreatmentBuprenorphine used in TreatmentNaltrexone used in Treatment
Detox services
Alcohol DetoxificationBenzodiazepines DetoxificationCocaine DetoxificationMethamphetamines detoxificationOpioids detoxificationMedication routinely used during detoxification
Payment accepted
MedicareMedicaidCash or self-paymentState-financed health insurance plan other than Medicaid
Ages served
Young AdultsAdultsSeniors
Accreditation
State substance use treatment agencyState department of healthCommission on Accreditation of Rehabilitation Facilities (CARF)Hospital licensing authorityThe Joint CommissionSAMHSA certification for opioid treatment program (OTP)Drug Enforcement Agency (DEA)
Free & confidential, 24/7
Not sure which program fits? Talk it through with someone who can help.
OutpatientOutpatient methadone/buprenorphine or naltrexone treatmentRegular outpatient treatmentFederal, or any government funding for substance use treatment programsNo payment accepted
OutpatientOutpatient methadone/buprenorphine or naltrexone treatmentRegular outpatient treatmentFederal, or any government funding for substance use treatment programsMedicare